Selumetinib
CAS 606143-52-6Small Molecule
Overview
Selumetinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1614701).
Patent & exclusivity (US)
Per the FDA Orange Book (4 approved US products), the latest listed US patent on Selumetinib expires 26 Mar 2029 and exclusivity 19 Nov 2032. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
- Canonical SMILES
- CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
- InChIKey
- CYOHGALHFOKKQC-UHFFFAOYSA-N
Verified Supplier Partner
Do you supply Selumetinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.